Allergan Viokace Tablets Recall: Subpotent Drug Risk
Allergan recalls 100-count Viokace tablets (NDC 58914-117-10) due to subpotent drug stability issues. This affects prescription-only enzyme supplements for pancreatic enzyme replacement.
Lower-risk recall
Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.
Contact the company
What happened, in plain English
Allergan is recalling 20,880 USP units of Viokace tablets because stability testing showed the product doesn't meet enzyme profile specifications. This means the medication may not work as intended for people with pancreatic insufficiency. Read more at govinfonow.com/recall/41033-allergan-viokace-tablets-recall-subpotent-drug-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/41033-allergan-viokace-tablets-recall-subpotent-drug-risk · Updated October 7, 2026 · FDA enforcement record: FDA #D-0154-2018
Cite this page
“Allergan Viokace Tablets Recall: Subpotent Drug Risk.” GovInfoNow, updated October 7, 2026. https://govinfonow.com/recall/41033-allergan-viokace-tablets-recall-subpotent-drug-risk. Based on FDA recall #D-0154-2018 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0154-2018%22&limit=1).
Why it’s dangerous
The tablets were tested for stability but failed to meet enzyme profile specifications. This means the medication may not provide the intended digestive enzyme function when taken.
Who’s affected
Prescription patients using Viokace tablets for pancreatic enzyme replacement. Those with the specific lot number 160741A (expiring February 2018) are most at risk.
How to tell if you have this one
Check for the lot number 160741A on the Viokace tablets packaging. The product is a 100-count bottle with 20,880 USP units, prescription-only, manufactured in Canada.
- Brand
Allergan- Category
Drug
What to do — step by step
Check Product Details
Look for the lot number 160741A on the Viokace tablets packaging.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “U.S.A. nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 18 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
What should I do if I have the recalled product?
The recall does not include a specific remedy, so you should check with your healthcare provider about whether to continue using the product.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0154-2018 (December 4, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0154-2018 to see it in context.
- Plain-language summary written by qwen3:4b on October 7, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.